MA
CRNX icon

Montag & Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Montag & Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$875 – 1008
2025
Q3 		$875 Buy
+21
New +$671 ﹤0.01% 1031

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Montag & Associates's CRNX Position: Q4 2025 in Review

Montag & Associates sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 21 shares — an estimated $875 sold.

Montag & Associates first reported a position in CRNX in Q3 2025 and held it in 1 quarter. The position peaked at $875 in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Montag & Associates reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 21 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $875.
  • Montag & Associates first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Crinetics Pharmaceuticals position peaked at $875 in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.